- Home
- RMCF vs JSPR Comparison
RMCF vs JSPR Comparison
Compare RMCF & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | JSPR |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 23.1M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCF | JSPR |
|---|---|---|
| Price | $2.07 | $0.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 47.4K | ★ 269.3K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.14 | $0.62 |
| 52 Week High | $2.99 | $7.19 |
Technical Indicators
Market Signals| Indicator | RMCF | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 36.02 | 38.41 |
| Support Level | $1.47 | $0.62 |
| Resistance Level | $2.18 | $1.03 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 1.63 | 11.24 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.